Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Mettetal, JT"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology; Jun2017, Vol. 6 Issue 6, p357-364, 8p
Autor:
Yang, K, Battista, C, Woodhead, JL, Stahl, SH, Mettetal, JT, Watkins, PB, Siler, SQ, Howell, BA
Publikováno v:
Clinical Pharmacology & Therapeutics; Apr2017, Vol. 101 Issue 4, p501-509, 9p
Autor:
Venkatakrishnan, K, Friberg, LE, Ouellet, D, Mettetal, JT, Stein, A, Trocóniz, IF, Bruno, R, Mehrotra, N, Gobburu, J, Mould, DR
Publikováno v:
Clinical Pharmacology & Therapeutics; Jan2015, Vol. 97 Issue 1, p37-54, 18p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Willis BS; Bioscience, Early Oncology, AstraZeneca, Boston, USA., Mongeon K; Bioscience, Early Oncology, AstraZeneca, Boston, USA., Dry H; Bioscience, Early Oncology, AstraZeneca, Boston, USA., Neveras IL; Bioscience, Early Oncology, AstraZeneca, Boston, USA., Bryan N; Bioscience, Early Oncology, AstraZeneca, Boston, USA., Pandya M; Bioscience, Early Oncology, AstraZeneca, Boston, USA., Roderick-Richardson J; Bioscience, Early Oncology, AstraZeneca, Boston, USA., Xu W; Department of Medicine A, Haematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany., Yang L; Department of Medicine A, Haematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany., Rosen A; Bioscience, Early Oncology, AstraZeneca, Boston, USA., Reimer C; Bioscience, Early Oncology, AstraZeneca, Boston, USA., Tuskova L; Institute of Pathological Physiology, First Faculty of Medicine, Charles University Prague, Prague, Czech Republic., Klener P; Institute of Pathological Physiology, First Faculty of Medicine, Charles University Prague, Prague, Czech Republic., Mettetal JT; Bioscience, Early Oncology, AstraZeneca, Boston, USA., Lenz G; Department of Medicine A, Haematology, Oncology, and Pneumology, University Hospital Münster, Münster, Germany., Barry ST; Bioscience, Early Oncology, AstraZeneca, Cambridge, UK. simon.t.barry@astrazeneca.com.
Publikováno v:
Leukemia [Leukemia] 2024 Sep 16. Date of Electronic Publication: 2024 Sep 16.
Autor:
Vasalou C; Clinical Pharmacology & Safety Sciences, Waltham, Massachusetts, USA., Proia TA; Translational Medicine, Waltham, Massachusetts, USA., Kazlauskas L; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Przybyla A; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Sung M; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Mamidi S; AstraZeneca Research & Development, Cambridge, UK., Maratea K; Clinical Pharmacology & Safety Sciences, Waltham, Massachusetts, USA., Griffin M; Clinical Pharmacology & Safety Sciences, Waltham, Massachusetts, USA., Sargeant R; Clinical Pharmacology & Safety Sciences, Cambridge, UK., Urosevic J; AstraZeneca Research & Development, Cambridge, UK., Rosenbaum AI; Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, South San Francisco, California, USA., Yuan J; Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, South San Francisco, California, USA., Aluri KC; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Ramsden D; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Hariparsad N; AstraZeneca Research & Development, Waltham, Massachusetts, USA., Jones RDO; AstraZeneca Research & Development, Cambridge, UK., Mettetal JT; AstraZeneca Research & Development, Waltham, Massachusetts, USA.
Publikováno v:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Jun; Vol. 13 (6), pp. 994-1005. Date of Electronic Publication: 2024 Mar 26.
Autor:
Bashi AC; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Coker EA; Wellcome Sanger Institute, Cambridge, United Kingdom., Bulusu KC; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Jaaks P; Wellcome Sanger Institute, Cambridge, United Kingdom., Crafter C; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Lightfoot H; Wellcome Sanger Institute, Cambridge, United Kingdom., Milo M; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., McCarten K; Wellcome Sanger Institute, Cambridge, United Kingdom., Jenkins DF; Oncology R&D, AstraZeneca, Waltham, Massachusetts., van der Meer D; Wellcome Sanger Institute, Cambridge, United Kingdom., Lynch JT; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Barthorpe S; Wellcome Sanger Institute, Cambridge, United Kingdom., Andersen CL; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Barry ST; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Beck A; Wellcome Sanger Institute, Cambridge, United Kingdom., Cidado J; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Gordon JA; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Hall C; Wellcome Sanger Institute, Cambridge, United Kingdom., Hall J; Wellcome Sanger Institute, Cambridge, United Kingdom., Mali I; Wellcome Sanger Institute, Cambridge, United Kingdom., Mironenko T; Wellcome Sanger Institute, Cambridge, United Kingdom., Mongeon K; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Morris J; Wellcome Sanger Institute, Cambridge, United Kingdom., Richardson L; Wellcome Sanger Institute, Cambridge, United Kingdom., Smith PD; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Tavana O; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Tolley C; Wellcome Sanger Institute, Cambridge, United Kingdom., Thomas F; Wellcome Sanger Institute, Cambridge, United Kingdom., Willis BS; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Yang W; Wellcome Sanger Institute, Cambridge, United Kingdom., O'Connor MJ; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., McDermott U; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Critchlow SE; Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Drew L; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Fawell SE; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Mettetal JT; Oncology R&D, AstraZeneca, Waltham, Massachusetts., Garnett MJ; Wellcome Sanger Institute, Cambridge, United Kingdom.
Publikováno v:
Cancer discovery [Cancer Discov] 2024 May 01; Vol. 14 (5), pp. 846-865.
Autor:
Pfeifer M; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK.; Leibniz-Institute of Virology (LIV) and University hospital Hamburg-Eppendorf (UKE), Hamburg, Germany., Brammeld JS; Wellcome Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK., Price S; Wellcome Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK., Pilling J; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Bhavsar D; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Farcas A; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Bateson J; Wellcome Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK., Sundarrajan A; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Miragaia RJ; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Guan N; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Arnold S; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Tariq L; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Grondine M; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Talbot S; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Guerriero ML; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., O'Neill DJ; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Young J; Wellcome Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK., Company C; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Dunn S; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Thorpe H; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Martin MJ; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Maratea K; Clinical Pharmacology & Safety, BioPharmaceuticals R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Barrell D; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Ahdesmaki M; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Mettetal JT; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., Brownell J; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK., McDermott U; Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge, CB2 0RE, UK. ultan.mcdermott@astrazeneca.com.
Publikováno v:
Communications biology [Commun Biol] 2024 Apr 24; Vol. 7 (1), pp. 497. Date of Electronic Publication: 2024 Apr 24.
Autor:
Mason-Osann E; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts., Pomeroy AE; Department of Pharmacology, Computational Medicine Program, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Palmer AC; Department of Pharmacology, Computational Medicine Program, UNC Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina., Mettetal JT; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts.
Publikováno v:
Blood cancer discovery [Blood Cancer Discov] 2024 Mar 01; Vol. 5 (2), pp. 95-105.